CD20-directed CAR-T cell therapy (Cellular Biomedicine)

N/A

Report date: 2026/02/12 20:00:14

Base Information

Drug NameCD20-directed CAR-T cell therapy (Cellular Biomedicine)
Drug Alias NameC-CAR066
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAbelZeta Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Tongji HospitalJanssen Research & Development LlcCellular Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A